Magnesium supplementation and metabolic profiles in poly cystic ovary syndrome (pcos)

Effect of magnesium supplementation on metabolic profile and sex hormone levels in overweight women with poly cystic ovary syndrome (pcos)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201306161485N11

Enrollment

Registered

2014-06-15

Start date

2014-04-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

polycystic ovary syndrome. Polycystic ovarian syndrome

Interventions

Intervention 1: Magnesium supplement, each tablet contains 250 mg magnesium oxide, 1 time a day for 8 week. Intervention 2: Placebo, similar color, odor and appearance to magnesium supplement, 1 time

Treatment - Drugs

Placebo

Magnesium supplement, each tablet contains 250 mg magnesium oxide, 1 time a day for 8 week

Placebo, similar color, odor and appearance to magnesium supplement, 1 time a day for 8 week

Eligibility

Sex/Gender

Female

Age

20 Years to 45 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: having poly cystic ovary syndrome according to the Rotterdam criteria; age between 20-45 years; not pregnant or lactating; non adherence to specific regime during the past 3 months; no smoking; no chronic diseases including, diabetes, cardio-vascular, liver, kidney, thyroid; non-food supplements; being overweight (BMI= 25 Kg/m2) Exclusion criteria: hormone therapy; pregnancy and lactation during the study; weight loss (more than 2.5 kg per month) during the study

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Serum Insulin Level. Timepoint: Baseline, week 8. Method of measurement: Enzyme-Linked Immunosorbent Assay.	—

Secondary

Measure	Time frame
Insulin Resistance. Timepoint: Baseline, week 8. Method of measurement: Calculation.;Fasting Blood Sugar. Timepoint: Baseline, week 8. Method of measurement: Commercial kits.;Quantitative Insulin Sensitivity Check Index. Timepoint: Baseline, week 8. Method of measurement: Calculation.;Homeostatic Model Assessment of Insulin Resistance. Timepoint: Baseline, week 8. Method of measurement: Calculation.;Homeostatic Model Assessment of Beta-cell function. Timepoint: Baseline, week 8. Method of measurement: Calculation.;High Density Lipoprotein. Timepoint: Baseline, week 8. Method of measurement: Commercial kits.;Low Density Lipoprotein. Timepoint: Baseline, week 8. Method of measurement: Commercial kits.;Total Cholesterol. Timepoint: Baseline, week 8. Method of measurement: Commercial kits.;Androgen. Timepoint: Baseline, week 8. Method of measurement: Commercial kits.;Testosterone. Timepoint: Baseline, week 8. Method of measurement: Commercial kits.;C-Reactive Protein. Timepoint: Baseline, week 8. Method of measurement: Enzyme-Linked Immunosorbent Assay.	—

Measure

Time frame

Insulin Resistance. Timepoint: Baseline, week 8. Method of measurement: Calculation.;Fasting Blood Sugar. Timepoint: Baseline, week 8. Method of measurement: Commercial kits.;Quantitative Insulin Sensitivity Check Index. Timepoint: Baseline, week 8. Method of measurement: Calculation.;Homeostatic Model Assessment of Insulin Resistance. Timepoint: Baseline, week 8. Method of measurement: Calculation.;Homeostatic Model Assessment of Beta-cell function. Timepoint: Baseline, week 8. Method of measurement: Calculation.;High Density Lipoprotein. Timepoint: Baseline, week 8. Method of measurement: Commercial kits.;Low Density Lipoprotein. Timepoint: Baseline, week 8. Method of measurement: Commercial kits.;Total Cholesterol. Timepoint: Baseline, week 8. Method of measurement: Commercial kits.;Androgen. Timepoint: Baseline, week 8. Method of measurement: Commercial kits.;Testosterone. Timepoint: Baseline, week 8. Method of measurement: Commercial kits.;C-Reactive Protein. Timepoint: Baseline, week 8. Method of measurement: Enzyme-Linked Immunosorbent Assay.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAhmad Esmaeilzade

Isfahan University of Medical Sciences

esmaillzadeh@hlth.mui.ac.ir+98 31 1792 2776

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026